Itraconazole for the treatment of cryptococcosis in cats.
Itraconazole was used in 35 cats with cryptococcosis. Treatment response was determined by comparing clinical signs before, during, and after treatment. It could not be evaluated in 7 cats because they died during treatment from causes unrelated to cryptococcosis. Of the remaining 28 cats, treatment response was classified as success in 16 cats (57%), as improvement in 8 cats (29%), and as a failure in 4 (14%). The failures were due to death or euthanasia from drug toxicity (1 cat), progressive fungal disease (2 cats), and relapse 1 year after treatment (1 cat). The cats that improved did not undergo a 1-year posttreatment evaluation because they were lost to follow-up (3 cats), died or were euthanatized for other reasons (4 cats), or had a noncompliant owner (1 cat). For the 16 cats in which treatment was successful, the median itraconazole dose was 13.8 mg/kg body weight daily (range, 10.9 to 26.7 mg/kg/d), and the median duration of treatment was 8.5 months (range, 4 to 16 months). Five of these cats had previously been treated unsuccessfully with ketoconazole.
Medleau
L
L
Department of Small Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens 30602.
Jacobs
G J
GJ
Marks
M A
MA
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D003453:Cryptococcosis / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D017964:Itraconazole / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome
D017964:Itraconazole; D000410:Alanine Transaminase